Compare TSBK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | ALDX |
|---|---|---|
| Founded | 1915 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 293.0M |
| IPO Year | 1998 | 2014 |
| Metric | TSBK | ALDX |
|---|---|---|
| Price | $36.92 | $5.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 14.1K | ★ 854.1K |
| Earning Date | 01-26-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 24.24 | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $83,726,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | ★ 11.15 | N/A |
| 52 Week Low | $27.51 | $1.14 |
| 52 Week High | $38.28 | $7.20 |
| Indicator | TSBK | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 61.32 |
| Support Level | $36.23 | $5.05 |
| Resistance Level | $37.75 | $5.65 |
| Average True Range (ATR) | 0.80 | 0.31 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 60.25 | 84.16 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.